CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® ...

Vote in the ASCO Election by December 8 at 3:00 PM (ET). ASCO encourages all eligible members to cast their ballots in the ASCO Election.

Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and ...